Safety assessment of bone marrow derived MSC grown in platelet-rich plasma

• Main Authors: Shoji Fukuda, Shotaro Hagiwara, Satsuki Fukuda, Ryo Yakabe, Hiroko Suzuki, Shigeharu G. Yabe, Techuan Chan, Hitoshi Okochi
• Format: Article
• Language: English
• Published: Elsevier 2015-06-01
• Series: Regenerative Therapy
• Subjects: MSC; PRP; Angiogenesis
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352320415000115

The injection of endothelial progenitor cells and mononuclear cells derived from bone marrow at the ischemic region of peripheral artery disease patients is reported to be effective for therapeutic angiogenesis; however, these cell therapies require large amounts of bone marrow to obtain sufficient numbers of cells. To solve this problem, we attempted to culture bone-marrow-derived mesenchymal stem cells (BM-MSC), which are supposed to secrete several cytokines that promote angiogenesis. We also focused on using platelet-rich plasma (PRP) as a supplement for cell culture instead of fetal bovine serum. Human BM-MSC obtained from healthy volunteers expanded rapidly when cultured with 10% PRP prepared from their own blood. FACS analysis revealed that these cultured human MSC were homogeneous populations, and chromosomal analysis showed a normal karyotype. Moreover, the angiogenetic effect was apparent two weeks after human BM-MSC were injected into the ischemic muscle in SCID mice. Tumor formation was not detected three months after injection into SCID mice either subcutaneously or intramuscularly. To simulate clinical settings, canine BM-MSC were grown with canine PRP and injected into their ischemic muscles. We confirmed that donor cells existed in situ two and six weeks after operation without any side effects. These results suggest that cultured human BM-MSC can be a promising cell source for therapeutic angiogenesis.